Clinical trial NCT00532441: Erlotinib in Combination With Docetaxel in Advanced Hepatocellular and Biliary Tract Carcinomas
Official title: Phase II Trial of Erlotinib in Combination With Docetaxel in Advanced Hepatocellular and Biliary Tract Carcinomas: Hoosier Oncology Group GI06-101
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: PHASE2
Conditions: Hepatocellular Carcinoma
Lead sponsor: Hoosier Cancer Research Network
Sponsor class: OTHER
Collaborators: name: Sanofi
name: OSI Pharmaceuticals
First posted: 2007-09-20
Enrollment: 25
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: An unmet medical need exists for the successful therapy of patients with advanced hepatocellular and biliary tract malignances, with few and short lived disease responses to chemotherapy for both advanced stage hepatic and biliary carcinomas. Pre-clinical data shows cooperative antitumor activity between an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor and taxanes. The efficacy of erlotinib in combination with docetaxel will be assessed in this trial.

Detailed description: Outline: This is a multi-center study.

Patients who meet eligibility criteria will receive treatment as follows until disease progression or excessive toxicities:

* Erlotinib 150 mg p.o. daily on days 2-7, 9-14, 16-28
* Docetaxel 30 mg/m2 IV over 30 min weekly x 3 weeks on days 1, 8, 15

Treatment cycle = 28 days

Performance Status: Eastern Cooperative Oncology Group (ECOG) performance status 0 to 2

Life expectancy: At least 12 weeks

Hematopoietic:

* Absolute neutrophil count (ANC) \> 1000 mm3
* Platelet count \> 75,000 mm3
* Hemoglobin \> 8 g/dL

Hepatic:

* Bilirubin \< 2.0 x upper limit of normal (ULN)
* Transaminases (AST, ALT) \< 5.0 x ULN if alkaline phosphatase is \< 2.5 x ULN, or alkaline phosphatase \< 5 x ULN if transaminases are \< 1.5 x ULN.
* If not on anticoagulation: PT \< 4 seconds above ULN; INR \< 1.5; PTT \< 1.3 x ULN.
* If on therapeutic anticoagulation, patients may have an INR \> 1.5 and PTT within therapeutic range; INR will be monitored weekly until stable.
* Serum Albumin \> 3.0

Renal:

* Creatinine clearance of \> 60 ml/ min (by Cockcroft-Gault)

Pulmonary:

* Not specified

Eligibility criteria: Inclusion Criteria:

* Histological or cytological proof of hepatocellular or biliary tract carcinomas, not amenable to curative resection or transplantation.
* Prior cancer treatment completed at least 30 days prior to being registered for protocol therapy and recovered from the acute toxicity effects of the regimen.
* Patients may have had radiofrequency ablation, cryosurgery or embolization, but must have documented progressive disease with the involved lesion, or at least one previously untreated lesion.
* Patients may have had ≤ 2 prior chemotherapy regimens.
* Prior radiation therapy allowed to \< 25% of the bone marrow at least 30 days prior to being registered for protocol therapy.
* Patients with biliary obstruction must have percutaneous transhepatic drainage or endoscopic stent placement prior to starting study treatment.
* Patients with a history of malignancy are eligible provided they have been curatively treated and demonstrate no evidence for recurrence of that cancer.
* Peripheral neuropathy ≤ grade 1.
* Patients must agree to abstain from frozen or fresh grapefruit or grapefruit juice for 5 days prior to, and during treatment.
* Patients must be willing to use an effective method of contraception (hormonal or barrier method of birth control; abstinence) while on treatment and for a 12 week period thereafter.
* Females of childbearing potential must have a negative pregnancy test within 7 days prior to being registered for protocol therapy.
* Written informed consent and HIPAA authorization for release of personal health information.
* Age ≥ 18 years at time of consent.

Exclusion Criteria:

* No previous treatment with EGFR inhibitors.
* No treatment with any investigational agent within 30 days prior to being registered for protocol therapy.
* No symptomatic brain metastasis. A subject with prior brain metastasis may be considered if they have completed their treatment for brain metastasis, no longer require corticosteroids, and are asymptomatic.
* No Child-Pugh B or C liver cirrhosis.
* No active corneal erosions or history of abnormal corneal sensitivity test.
* No history of aneurysm or arteriovenous malformation.
* No hemorrhage/bleeding event \> CTCAE Grade 3 within 30 days prior to begin registered for protocol therapy.
* No clinically significant infections as judged by the treating investigator.
* No condition that impairs patient's ability to swallow whole pills.
* No history of hypersensitivity to docetaxel or other drugs formulated with polysorbate 80.
* Females must not be breastfeeding.
* Patients who cannot avoid the following medications will be ineligible for the trial: midazolam, anti-mycotic agents (ketoconazole and related compounds), macrolide antibiotics (erythromycin and related compounds), nifedipine, phenobarbital, phenytoin, carbamazepine, and rifampin (induction) and anti-retrovirals (including ritonavir, saquinavir).

Primary outcomes:
measure: 16 Weeks Progression-free Survival
timeFrame: Start of treatment until disease progression per RECIST criteria up to 16 weeks
Secondary outcomes:
measure: Response Rate
timeFrame: 18 months
measure: Overall Survival
timeFrame: 18 Months
Other outcomes:
Locations:
city: Newark
country: United States
facility: Helen F. Graham Cancer Center
state: Delaware
city: Chicago
country: United States
facility: Northwestern University Feinberg School of Medicine
state: Illinois
city: Chicago
country: United States
facility: Rush-Presbyterian St. Luke's Medical Center
state: Illinois
city: Bloomington
country: United States
facility: Cancer Care Center of Southern Indiana
state: Indiana
city: Fort Wayne
country: United States
facility: Fort Wayne Oncology & Hematology, Inc
state: Indiana
city: Indianapolis
country: United States
facility: IN Onc/Hem Associates
state: Indiana
city: Indianapolis
country: United States
facility: Indiana University Cancer Center
state: Indiana
city: Indianapolis
country: United States
facility: Quality Cancer Center (MCGOP)
state: Indiana
city: Muncie
country: United States
facility: Medical Consultants, P.C.
state: Indiana
city: South Bend
country: United States
facility: Northern Indiana Cancer Research Consortium
state: Indiana
city: St. Louis
country: United States
facility: Siteman Cancer Center
state: Missouri
city: Omaha
country: United States
facility: Methodist Cancer Center
state: Nebraska
Study officials:
affiliation: Hoosier Oncology Group, LLC
name: Elena Gabriela Chiorean, M.D.
role: STUDY_CHAIR
References:
citation: Chiorean EG, Ramasubbaiah R, Yu M, Picus J, Bufill JA, Tong Y, Coleman N, Johnston EL, Currie C, Loehrer PJ. Phase II trial of erlotinib and docetaxel in advanced and refractory hepatocellular and biliary cancers: Hoosier Oncology Group GI06-101. Oncologist. 2012;17(1):13. doi: 10.1634/theoncologist.2011-0253. Epub 2011 Dec 30.